An assessment of the statistical methods used to analyse toxicology studies

Pharmaceutical Statistics

Volumn 10, Issue 6, 2011, Pages 477-484

  Jarvis, Philip ^a   Saul, Jim ^b   Aylott, Mike ^c   Bate, Simon ^d   Geys, Helena ^e   Sherington, John ^f  

^a ASTRAZENECA   (United Kingdom)

^b Department of Genetic and Molecular Toxicology   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d HUNTINGDON LIFE SCIENCES   (United Kingdom)

^e JANSSEN RESEARCH FOUNDATION   (Belgium)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

carcinogenicity; general toxicology; genetic toxicology; safety pharmacology

Indexed keywords

ARTICLE; CARCINOGENICITY; CENTRAL NERVOUS SYSTEM; CLINICAL ASSESSMENT; COMET ASSAY; DOG; GENETIC TOXICOLOGY; HUMAN; MICRONUCLEUS; NONHUMAN; OPEN FIELD TEST; ORGAN WEIGHT; PRACTICE GUIDELINE; PRODUCT SAFETY; STATISTICAL ANALYSIS; STUDY DESIGN; TELEMETRY; TOXICITY TESTING;

ANIMALS; CARCINOGENICITY TESTS; FEMALE; MALE; MUTAGENICITY TESTS; RESEARCH DESIGN; TOXICITY TESTS; TOXICOLOGY;

EID: 84855202555     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.527     Document Type: Article

References (31)

1. ICH M3(R2) Guideline. Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, January 2010.
2. ICH S5 Guideline. Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals, July 1997.
3. Addendum to ICH S6: Preclinical Safety Evaluation of Biotechnology- Derived Pharmaceuticals, October 2009.
4. Lovell D, Anderson D, Albanese R, Amphlett GE, Clare G, Ferguson R, Richold M, Papworth DG, Savage JRK,. Statistical analysis on in vivo cytogenetic assays. Statistical evaluation of mutagenicity test data, Kirkland J, (ed.). Cambridge University Press: Cambridge, 1989; 184-204.
5. Bright J, Aylott M, Bate S, Geys H, Jarvis P, Saul J, Vonk R,. Recommendations on the statistical analysis of the Comet assay. Pharmaceutical Statistics. Accepted for publication.
6. Stevens MT,. The value of relative organ weights. Toxicology 1976; 5: 311-318.
7. Shirley E,. The analysis of organ weight data. Toxicology 1997; 8: 13-22.
8. Shirley E, Newnham P,. The choice between analysis of variance and analysis of covariance with special reference to the analysis of organ weights in toxicology studies. Stats in Medicine 1984; 3: 85-91. (Pubitemid 14142279)
9. Takizawa T,. An unbiased comparison of organ weights when an inequality in body weight exists. Toxicology 1978; 9: 353-360. (Pubitemid 8341536)
10. Bailey SA, Zidell RH, Perry RW,. Relationships between organ weight and body/brain weight in the rat: What is the best analytical endpoint? Toxicologic Pathology 2004; 32: 448-466. (Pubitemid 38998937)
11. Sellers RS, Morton D, Michael B, Roome N, Johnson JK, Yano BL, Perry R, Schafer K,. Society of toxicologic pathology position paper: organ weight recommendations for toxicology studies. Toxicologic Pathology 2007; 35: 751-755.
12. Aylott M, Bate S, Collins S, Jarvis P, Saul J,. Review of the statistical analysis of the dog telemetry study. Pharmaceutical Statistics 2011; 10: 236-249.
13. Irwin S,. Comprehensive observational assessment: 1a. A systematic quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 1968; 13: 222-257.
14. Moser VC,. Approaches for assessing the validity of a functional observational battery. Neurotoxicological Teratology 1990; 12: 483-488. (Pubitemid 20342179)
15. Peto R, Pike MC, Day NE, Gray RG, Lee PN, Parish S, Peto J, Richards S, Wahrendorf J,. Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Supplement 2. WHO International Agency for Research on Cancer: Lyon, 1980; 311-426.
16. Schaarschmidt F, Sill M, Hothorn LA,. Poly-k-trend tests for survival adjusted analysis of tumor rates formulated as approximate multiple contrast test, Vol. 18, 2008.
17. CYTEL. StatXact 3 for windows: statistical software for exact nonparametric inference 1995.
18. Mitchard T, Jarvis P, Stewart J,. Assessment male rodent fertility in general toxicology six month studies. Submitted to Birth Defects Research (Part B) 2011.
19. Jarvis P, Srivastav S, Vogelwedde E, Stewart J, Mitchard T, Weinbauer G,. The cynomolgus monkey as a model for developmental toxicity studies: variability of pregnancy losses, statistical power estimates, and group size considerations. Birth Defects Research (Part B) 2010; 89: 175-187.
20. Hsu SU,. Multiple comparisons: theory and methods. Chapman and Hall: London, 1996: 175-180.
21. ICH S2A Guideline. Genotoxicity: Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals, April 1996.
22. ICH S2B Guideline. Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals, November 1997.
23. ICH S2(R1) Draft Guideline. Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use, March 2008.
24. ICH S7A Guideline. Safety Pharmacology Studies for Human Pharmaceuticals, July 2001.
25. ICH S7B Guideline. Non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by Human Pharmaceuticals, October 2005.
26. ICH S5A Guideline. Detection of Toxicity to Reproduction for Medicinal Products, September 1994.
27. ICH S5A Guideline. Detection of Toxicity to Reproduction for Medicinal Products, April 1996.
28. ICH S1A Guideline. The Need for Long-term Rodent Carcinogenicity Studies of Pharmaceuticals, March 1996.
29. ICH S1B Guideline. Testing for Carcinogenicity of Pharmaceuticals, 1998.
30. ICH S1C(R2) Guideline. Dose Selection for Carcinogenicity Studies, September 2008.
31. Shapiro A,. Towards a unified theory of inequality constrained testing in multivariate analysis. International Statistical Review 1988; 56: 49-62.